Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang, Danni Tian, Xiaodong Ren, et al.
European Journal of Medicinal Chemistry (2018) Vol. 151, pp. 315-326
Closed Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells
Sun‐Hee Jang, Eui-Jong Kwon, Jennifer Lee
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 905-905
Open Access | Times Cited: 296
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 203
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 164
B Cells in Rheumatoid Arthritis：Pathogenic Mechanisms and Treatment Prospects
Fengping Wu, Jinfang Gao, Jie Kang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 161
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 9, pp. 729-738
Open Access | Times Cited: 143
Phosphorylation-Inducing Chimeric Small Molecules
Sachini U. Siriwardena, Dhanushka N. P. Munkanatta Godage, Veronika M. Shoba, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 33, pp. 14052-14057
Closed Access | Times Cited: 138
Updates and Advances in Multiple Sclerosis Neurotherapeutics
Moein Amin, Carrie M. Hersh
Neurodegenerative Disease Management (2022) Vol. 13, Iss. 1, pp. 47-70
Open Access | Times Cited: 98
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 98
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
Marcus Maurer, William Berger, Ana M. Giménez‐Arnau, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 6, pp. 1498-1506.e2
Open Access | Times Cited: 88
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Monica Margoni, Paolo Preziosa, Massimo Filippi, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1316-1334
Open Access | Times Cited: 83
Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
Saul Jaime‐Figueroa, Alexandru D. Buhimschi, Momar Toure, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 30, Iss. 3, pp. 126877-126877
Open Access | Times Cited: 81
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Zhouling Xie, Xiaoxiao Yang, Yajun Duan, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1283-1345
Closed Access | Times Cited: 71
Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein
Shijie Fan, Liyan Yue, Wei Wan, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 50, pp. 26105-26114
Open Access | Times Cited: 66
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
Philipp von Hundelshausen, Wolfgang Siess
Cancers (2021) Vol. 13, Iss. 5, pp. 1103-1103
Open Access | Times Cited: 63
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
Martin Kaul, Peter End, Maciej Cabanski, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 5, pp. 1756-1768
Open Access | Times Cited: 59
Antitumor Activity of s-Triazine Derivatives: A Systematic Review
Qiuzi Dai, Qinsheng Sun, Xiaorong Ouyang, et al.
Molecules (2023) Vol. 28, Iss. 11, pp. 4278-4278
Open Access | Times Cited: 27
A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome
Karla Misselbeck, Silvia Parolo, Francesca Lorenzini, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 65
Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
Yifan Feng, Weiming Duan, Xiaochuan Cu, et al.
Expert Opinion on Therapeutic Patents (2019) Vol. 29, Iss. 4, pp. 217-241
Closed Access | Times Cited: 58
Monomeric Targeted Protein Degraders
Emily J. Hanan, Jun Liang, Xiaojing Wang, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 20, pp. 11330-11361
Closed Access | Times Cited: 57
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Marzia Palma, Tom A. Mulder, Anders Österborg
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Fansheng Ran, Yun Liu, Chen Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114009-114009
Closed Access | Times Cited: 52
The Development of BTK Inhibitors: A Five-Year Update
Bruno Tasso, Andrea Spallarossa, Eleonora Russo, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7411-7411
Open Access | Times Cited: 50
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Datong Zhang, Gong He, Fancui Meng
Molecules (2021) Vol. 26, Iss. 16, pp. 4907-4907
Open Access | Times Cited: 49
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
Chiara Brullo, Carla Villa, Bruno Tasso, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7641-7641
Open Access | Times Cited: 47
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top